CA-PACKETFABRIC
PacketFabric , an innovator of on-demand connectivity to the secure, private internet, today announced it launched flat rate pricing for hybrid cloud connectivity across the U.S. and Europe. With this innovative pricing strategy, PacketFabric continues to lead the market disruption of networking and cloud computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005337/en/
PacketFabric’s new democratized pricing is $100 per month for hosted hybrid cloud connections up to 1Gbps, for both metro and long-haul capacity in the United States and Europe. With this new pricing strategy, PacketFabric is making cloud connectivity egalitarian across the tech landscape.
“Cloud is the future, and it shouldn’t be exclusive,” said PacketFabric CEO Dave Ward. “That’s why we sought a way to democratize it. Now with PacketFabric’s flat rate pricing, companies from emerging businesses to large enterprises can have affordable access to the cloud.”
According to Gartner, “cost optimization will be crucial to drive cloud adoption, and by 2024, all legacy applications will be migrated to public cloud infrastructure.”
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” continued Ward. “We’ve been disrupting the market since we launched PacketFabric’s Network-as-a-Service (NaaS) platform in 2017, and we continue to lead the way forward.”
PacketFabric’s NaaS orchestrates and guarantees connectivity between collocation facilities, clouds, and offers private network interconnection across the globe. The NaaS platform is private, secure, reliable and scalable, plus it’s fully redundant. PacketFabric is a women-founded technology start-up, launched by industry veterans Jezzibell Gilmore, PacketFabric’s Chief Commercial Officer, and Anna Claiborne, Senior Vice President of Product and Engineering for PacketFabric.
Ward, a prolific technologist, expands on PacketFabric’s strategy in his recent blog post , “Democratizing Access to the Cloud, Disrupting the Business of Getting to the Cloud.”
About PacketFabric
PacketFabric redefines how the enterprise moves data by automating network connectivity services. Leveraging an entirely automated SDN-based network architecture and the latest in optical and packet switching technology, PacketFabric enables dynamic, real-time connectivity services between more than hundreds of premier colocation facilities across many global markets. The PacketFabric Network-as-a-Service (NaaS) platform delivers simple, cost-effective, and scalable network deployment via its advanced Application Program Interface (API) and web portal. PacketFabric was named one of the “10 Hottest Networking Startups in 2020” by CRN and a 2020 “Cool Vendor in Enhanced Internet Services and Cloud Connectivity” by Gartner. PacketFabric investors include NantWorks and Digital Alpha Advisors. For more information, visit packetfabric.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005337/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom